Royalty Pharma PLC (RPRX) News
Filter RPRX News Items
RPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RPRX News Highlights
- RPRX's 30 day story count now stands at 5.
- Over the past 16 days, the trend for RPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ASND and RARE are the most mentioned tickers in articles about RPRX.
Latest RPRX News From Around the Web
Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.
Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerNEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenur |
Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?With its stock down 10% over the past three months, it is easy to disregard Royalty Pharma (NASDAQ:RPRX). It is... |
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. “This transaction reflects the significant value of Skytrofa. We |
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue. “This transaction reflects the significant value of SKYTROFA. We |
Royalty Pharma to Present at Upcoming Investor ConferencesNEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 18th Annual BioPharma Conference on Wednesday, September 6 at 11:20 a.m. ETMorgan Stanley’s 21st Annual Global Healthcare Conference on Tuesday, September 12 at 12:55 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and- |
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)Transaction provides Ferring with significant non-dilutive capital to support the manufacturing capacity expansion, commercialization and further clinical development of Adstiladrin for bladder cancer patients in the United States NEW YORK and SAINT PREX, Switzerland, Aug. 24, 20 |
Shareholders in Royalty Pharma (NASDAQ:RPRX) are in the red if they invested three years agoMany investors define successful investing as beating the market average over the long term. But if you try your hand... |
Royalty Pharma Reports Second Quarter 2023 ResultsNet cash provided by operating activities (GAAP) of $608 million and Adjusted Cash Receipts(1) (non-GAAP) of $545 millionAnnounced transactions of up to $1.7 billion year-to-date, including $659 million in upfront paymentsRaising 2023 guidance: Adjusted Cash Receipts(1) (non-GAAP) expected to be $2,900 to $2,975 million NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2023 and raised full-year 2023 guidance f |
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference ca |
Royalty Pharma Declares Third Quarter 2023 DividendNEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of business on August 18, 2023. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical i |